Cargando…

Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo

Encorafenib (LGX818, trade name Braftovi), a novel BRAF inhibitor, has been approved for the treatment of melanoma and colorectal cancer. In the present work, we evaluated encorafenib’s possible antagonistic effects on the pharmacokinetic mechanisms of multidrug resistance (MDR), as well as its perp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yu, Vagiannis, Dimitrios, Budagaga, Youssif, Sabet, Ziba, Hanke, Ivo, Rozkoš, Tomáš, Hofman, Jakub
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785850/ https://www.ncbi.nlm.nih.gov/pubmed/36559089 http://dx.doi.org/10.3390/pharmaceutics14122595

Ejemplares similares

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study
por: Sabet, Ziba, et al.
Publicado: (2022)

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
por: Vagiannis, Dimitrios, et al.
Publicado: (2021)

Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

Encorafenib overdose: Various toxicities: case report
Publicado: (2021)

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022)

ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity
por: Zhou, Kaijia, et al.
Publicado: (2020)

Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma
por: Seethapathy, Harish, et al.
Publicado: (2020)

Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
por: Gravbrot, Nicholas, et al.
Publicado: (2019)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma
por: Kim, Dae Won, et al.
Publicado: (2023)

Dominantly acting ABCC8 mutations in patients with medically unresponsive hyperinsulinaemic hypoglycaemia
por: Flanagan, SE, et al.
Publicado: (2011)

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2022)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
por: Issac, Aaron G., et al.
Publicado: (2022)

Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme
por: Vagiannis, Dimitrios, et al.
Publicado: (2020)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [ (14)C] encorafenib in healthy male subjects
por: Wollenberg, Lance, et al.
Publicado: (2023)

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023)

Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome
por: Young, Peter A., et al.
Publicado: (2021)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo–In Vitro–In Silico Approach
por: Piscitelli, Joseph, et al.
Publicado: (2023)

Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: In Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary Flavonoids
por: Saito, Hiroki, et al.
Publicado: (2020)

LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR‐134/Myc/ABCC1 axis in glioma
por: Wu, Changwu, et al.
Publicado: (2020)

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
por: Megías-Vericat, Juan Eduardo, et al.
Publicado: (2019)

Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder
por: van den Tempel, Nathalie, et al.
Publicado: (2018)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
por: Holbrook, Kourtney, et al.
Publicado: (2019)

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
por: Schulz, Alexander, et al.
Publicado: (2022)

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF(V600E) Protein
por: Marini, Elisabetta, et al.
Publicado: (2022)

Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines
por: Low, Floren G., et al.
Publicado: (2020)

Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib
por: Ross, Kayleigh C., et al.
Publicado: (2018)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
por: Sun, James, et al.
Publicado: (2018)

Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines
por: Patel, Vikas, et al.
Publicado: (2021)

Implications of ABCC4–Mediated cAMP Efflux for CRC Migration
por: Kryczka, Jakub, et al.
Publicado: (2020)

ABCC9 Is Downregulated and Prone to Microsatellite Instability on ABCC9tetra in Canine Breast Cancer
por: Hao, Pan, et al.
Publicado: (2022)

Exploring Metabolic Signatures of Ex Vivo Tumor Tissue Cultures for Prediction of Chemosensitivity in Ovarian Cancer
por: Mendes, Rita, et al.
Publicado: (2022)

Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma
por: Bagnoli, Marina, et al.
Publicado: (2013)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
por: Pickles, Oliver J., et al.
Publicado: (2020)

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
por: Augustyn, Kourtney, et al.
Publicado: (2023)

Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel
por: Fonseca, Joana, et al.
Publicado: (2016)

Three novel ABCC5 splice variants in human retina and their role as regulators of ABCC5 gene expression
por: Stojic, Jelena, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_i9hm0bndqlcq0urbquaa186nu6